Success Metrics

Completion Rate
0%(0/4)
Active Trials
0(0%)
Terminated
4(57%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_3
2
29%
Ph phase_2
2
29%

Phase Distribution

3

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 6 finished

Non-Completion Rate

100.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Terminated(6)
Other(1)

Detailed Status

Terminated4
Withdrawn2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 22 (28.6%)
Phase 32 (28.6%)

Trials by Status

suspended114%
terminated457%
withdrawn229%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_1

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

NCT06110195
terminatedphase_3

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

NCT05386550
terminatedphase_1

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
terminatedphase_3

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer

NCT05930938
withdrawnphase_1

Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

NCT06463184
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06110195Phase 1

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

Terminated
NCT05386550Phase 3

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Terminated
NCT06056310Phase 1

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Terminated
NCT05930938Phase 3

Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer

Terminated
NCT06463184Phase 1

Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)

Withdrawn
NCT05724602Phase 2

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Suspended
NCT06084845Phase 2

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7